The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo
Abstract
Mdm2 has been shown to promote its own ubiquitination and the ubiquitination of the p53 tumour suppressor by virtue of its E3 ubiquitin ligase activity. This modification targets Mdm2 and p53 for degradation by the proteasome. The p14ARF tumour suppressor has been shown to inhibit degradation of p53 mediated by Mdm2. Several models have been proposed to explain this effect of p14ARF. Here we have compared the effects of p14ARF overexpression on the in vivo ubiquitination of p53 and Mdm2. We report that the inhibition of the Mdm2-mediated degradation of p53 by p14ARF is associated with a decrease in the proportion of ubiquitinated p53. The levels of polyubiquitinated p53 decreased preferentially compared to monoubiquitinated species. p14ARF overexpression increased the levels of Mdm2 but it did not reduce the overall levels of ubiquitinated Mdm2 in vivo. This is unexpected because p14ARF has been reported to inhibit the ubiquitination of Mdm2 in vitro. In addition we show that like p14ARF, the proteasome inhibitor MG132 can promote the accumulation of Mdm2 in the nucleolus and that this can occur in the absence of p14ARF expression. We also show that the mutation of the nucleolar localization signal of Mdm2 does not impair the overall ubiquitination of Mdm2 but is necessary for the effective polyubiquitination of p53. These studies reveal important differences in the regulation of the stability of p53 and of Mdm2.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p14ARF inhibits the poly-ubiquitylation of p53 while the ubiquitylation of Mdm2 is unaffected (Xirodimas et al., 2001).”
From Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms (2001) · cites this paper as Xirodimas et al., 2001
In the citing paper
“While p14ARF also stabilizes Mdm2 and blocks Mdm2-mediated degradation of p53, its effects on p53 and Mdm2 ubiquitylation are the opposite of Mdmx.”
From Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms (2001) · cites this paper as Xirodimas et al., 2001
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“Interaction of p53 with Mdm2 results in a dramatic reduction of the p53 levels in vivo (Haupt et al., 1997; Kubbutat et al., 1997; Bottger et al., 1997).”
Backgroundp53: puzzle and paradigm.Preprint
Ko, L. J., & Prives, C. L. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,346
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Recognition of the polyubiquitin proteolytic signal
Thrower, J. S., Hoffman, L. M., Rechsteiner, M., & Pickart, C. M. (2000) · The EMBO Journal · doi:10.1093/emboj/19.1.94 · Cited by 1,769
Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521
The ubiquitin–proteasome pathway: on protein death and cell life
Ciechanover, A. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.24.7151 · Cited by 1,419
Stott, F. J., Bates, S., James, M. C., McConnell, B. B., Starborg, M., Brookes, S., Palmero, I., Ryan, K. M., Hara, E., Vousden, K. H., et al. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,178
Research works printed but not linked: 1
- Chen J, Marechal V, Levine AJ . 1993 Mol. Cell Biol. 13: 4107–4114 · DOI
Cited by
Sorted by citations
Items 101–168 of 168
He, H., Gu, Q., Zheng, M., Normolle, D. P., & Sun, Y. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn021 · Cited by 35
Latonen, L., Kurki, S., Pitkänen, K., & Laiho, M. (2003) · Cellular Signalling · doi:10.1016/s0898-6568(02)00044-x · Cited by 37
Oligomerization of the Human ARF Tumor Suppressor and Its Response to Oxidative Stress
Ménendez, S., Khan, Z., Coomber, D., Lane, D. P., Higgins, M., Koufali, M. M., & Laı́n, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211007200 · Cited by 35
Self-citationThe p66 and p12 subunits of DNA polymerase δ are modified by ubiquitin and ubiquitin-like proteins
Liu, G., & Warbrick, E. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.08.049 · Cited by 33
Productive human herpesvirus 6 infection causes aberrant accumulation of p53 and prevents apoptosis
Takemoto, M., Mori, Y., Ueda, K., Kondo, K., & Yamanishi, K. (2004) · Journal of General Virology · doi:10.1099/vir.0.19626-0 · Cited by 32
Physical and Functional Interaction between Ribosomal Protein L11 and the Tumor Suppressor ARF
Dai, M., Challagundla, K. B., Sun, X., Palam, L. R., Zeng, S. X., Wek, R. C., & Lu, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.311902 · Cited by 31
The Oncoprotein SS18-SSX1 Promotes p53 Ubiquitination and Degradation by Enhancing HDM2 Stability
D’Arcy, P., Maruwge, W., Ryan, B. A., & Brodin, B. A. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0176 · Cited by 32
ZNF668 Functions as a Tumor Suppressor by Regulating p53 Stability and Function in Breast Cancer
Hu, R., Peng, G., Dai, H., Breuer, E.-K. Y., Stemke‐Hale, K., Li, K., Gonzalez-Angulo, A. M., Mills, G. B., & Lin, S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0853 · Cited by 31
Stabilization of p73 by Nuclear IκB Kinase-α Mediates Cisplatin-induced Apoptosis
Furuya, K., Ozaki, T., Hanamoto, T., Hosoda, M., Hayashi, S., Barker, P. A., Takano, K., Matsumoto, M., & Nakagawara, A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610522200 · Cited by 30
Zhang, Z., Liu, X., Li, L., Yang, Y., Yang, J., Wang, Y., Wu, J., Wu, X., Shan, L., Pei, F., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021107974 · Cited by 29
Modeling the response of a tumor-suppressive network to mitogenic and oncogenic signals
Tian, X., Huang, B. Y., Zhang, X., Lu, M., Liu, F., Onuchic, J. N., & Wang, W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1702412114 · Cited by 28
Pizzorno, A., Dubois, J., Machado, D. B. B., Cartet, G., Traversier, A., Julien, T., Lina, B., Bourdon, J., Rosa‐Calatrava, M., & Terrier, O. (2018) · Scientific Reports · doi:10.1038/s41598-018-22139-6 · Cited by 26
Transcription factor TAFII250 promotes Mdm2-dependent turnover of p53
Allende-Vega, N., Saville, M. K., & Meek, D. W. (2007) · Oncogene · doi:10.1038/sj.onc.1210209 · Cited by 26
Self-citationSelective induction of apoptosis by leptomycin B in keratinocytes expressing HPV oncogenes
Gray, L. J., Bjelogrlic, P., Appleyard, V. C. L., Thompson, A. M., Jolly, C., Laı́n, S., & Herrington, C. S. (2007) · International Journal of Cancer · doi:10.1002/ijc.22591 · Cited by 25
Self-citationHuart, A.-S., MacLaine, N. J., Narayan, V., & Hupp, T. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043391 · Cited by 27
Chaar, I., Amara, S., Elamine, O. E., Khiari, M., Ounissi, D., Khalfallah, T., Hmida, A. B., Mzabi, S. R., & Bouraoui, S. (2013) · Tumor Biology · doi:10.1007/s13277-013-1198-9 · Cited by 25
Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells
Wade, M. R., Li, Y. C., Matani, A. S., Braun, S. M. G., Milanesi, F., Rodewald, L. W., & Wahl, G. M. (2012) · Oncogene · doi:10.1038/onc.2011.625 · Cited by 25
Phosphorylation and Stabilization of TAp63γ by IκB Kinase-β
MacPartlin, M., Zeng, S. X., & Lu, H. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801394200 · Cited by 23
Overview of Approaches for Screening for Ubiquitin Ligase Inhibitors
Sun, Y. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)99043-5 · Cited by 23
A High-Throughput Screen Measuring Ubiquitination of p53 by Human mdm2
Murray, M. F., Jurewicz, A. J., Martin, J. D., Ho, T. F., Zhang, H., Johanson, K., Kirkpatrick, R. B., Ma, J., Lor, L. A., Thrall, S. H., et al. (2007) · SLAS DISCOVERY · doi:10.1177/1087057107308556 · Cited by 21
Inturi, R., Mun, K., Singethan, K., Schreiner, S., & Punga, T. (2017) · Journal of Virology · doi:10.1128/jvi.01154-17 · Cited by 19
Gene expression profiling in melanoma identifies novel downstream effectors of p14ARF
Packer, L., Pavey, S. J., Boyle, G. M., Stark, M. S., Ayub, A. L. P., Rizos, H., & Hayward, N. K. (2007) · International Journal of Cancer · doi:10.1002/ijc.22725 · Cited by 21
Vestey, S. B., Sen, C., Calder, C. J., Perks, C. M., Pignatelli, M. N., & Winters, Z. (2004) · Breast Cancer Research · doi:10.1186/bcr912 · Cited by 20
The p53 Tumor Suppressor Pathway and Cancer
Zambetti, G. P. (2005) · Springer eBooks · doi:10.1007/0-387-30127-5 · Cited by 20
Modification of MDMX by sumoylation
Pan, Y., & Chen, J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.012 · Cited by 20
Transcriptional repressor NIR interacts with the p53-inhibiting ubiquitin ligase MDM2
Heyne, K., Förster, J., Schüle, R., & Roemer, K. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1371 · Cited by 19
Discovery of Novel Proteasome Inhibitors Using a High-Content Cell-Based Screening System
Lavelin, I., Beer, A., Kam, Z., Rotter, V., Oren, M., Navon, A., & Geiger, B. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008503 · Cited by 17
Ko, T., Sharma, R., & Li, S. (2019) · Oncogene · doi:10.1038/s41388-019-1022-0 · Cited by 18
Functional characterization of novel germline TP53 variants in Swedish families
Kharaziha, P., Ceder, S., Axell, O., Krall, M., Fotouhi, O., Böhm, S., Laı́n, S., Borg, Å., Larsson, C., Wiman, K. G., et al. (2019) · Clinical Genetics · doi:10.1111/cge.13564 · Cited by 15
Self-citationChen, Y., Wang, Z., & Wu, H. (2014) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-014-3135-y · Cited by 13
Nuclear export inhibitor leptomycin B induces the appearance of novel forms of human Mdm2 protein
Ménendez, S., Higgins, M., Berkson, R., Edling, C. E., Lane, D. P., & Laı́n, S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600752 · Cited by 12
Self-citationCharacterization of two peptide epitopes on Mdm2 oncoprotein that affect p53 degradation
Balass, M., Kalef, E., Maya, R., Wilder, S., Oren, M., & Katchalski‐Katzir, E. (2002) · Peptides · doi:10.1016/s0196-9781(02)00147-x · Cited by 9
Gavrilova, A. A., Neklesova, M. V., Zagryadskaya, Y. A., Константинович, Т. К., Константинович, Т. К., & Fonin, A. V. (2024) · Biomolecules · doi:10.3390/biom14101333 · Cited by 10
Regulation of LIM-domain-binding 1 protein expression by ubiquitination of Lys134
Howard, P. W., Jue, S. F., Ransom, D. G., & Maurer, R. A. (2010) · Biochemical Journal · doi:10.1042/bj20091461 · Cited by 8
The E3 ubiquitin-protein ligase MDM2 is a novel interactor of the von Hippel–Lindau tumor suppressor
Falconieri, A., Minervini, G., Bortolotto, R., Piovesan, D., Lopreiato, R., Sartori, G., Pennuto, M., & Tosatto, S. C. E. (2020) · Scientific Reports · doi:10.1038/s41598-020-72683-3 · Cited by 7
Pizzolato, G., Moparthi, L., Pagella, P., Cantù, C., D’Arcy, P., & Koch, S. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107126 · Cited by 6
Regulation of Actinomycin D induced upregulation of Mdm2 in H1299 cells
Li, L., Cui, D., Zheng, S. J., Lou, H., & Tang, J. (2011) · DNA repair · doi:10.1016/j.dnarep.2011.10.010 · Cited by 6
Kim, K., Moretti, T., Park, S., & Kim, J. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/428136 · Cited by 6
Impact ofMDM2, TP53andP14ARFPolymorphisms on Endometrial Cancer Risk and Onset
Wujcicka, W. I., Zając, A. E., & Stachowiak, G. (2019) · In Vivo · doi:10.21873/invivo.11559 · Cited by 5
Li, J., Tang, Y., Huang, L., Yu, Q., Hu, G., & Yuan, X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158613 · Cited by 5
Ubiquitin Family Members in the Regulation of the Tumor Suppressor p53
Xirodimas, D. P., & Scheffner, M. (2010) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-1-4419-6676-6_10 · Cited by 5
Self-citationThe regulation of p53 synthesis.
Ponnuswamy, A., & Fåhræus, R. (2012) · PubMed · Cited by 3
Scaffold Proteins in Gastrointestinal Tumors as a Shortcut to Oncoprotein Activation
Li, C., Wang, H., Yao, H., Fang, J., & Xu, J. (2017) · Gastrointestinal Tumors · doi:10.1159/000477904 · Cited by 2
The prognostic value of MDM2 overexpression in superficial urothelial bladder carcinoma
Santos, L. L., Pereira, M. K., Costa, C., Amaro, T., Lameiras, C., Pereira, S., Lopes, P. S., Alonso, B. C., Koch, A., & Lopes, C. S. (2002) · Revista de Oncología · doi:10.1007/bf02832107 · Cited by 2
Identification of ubiquitinated proteins
Panasenko, O. O. (2014) · Materials and Methods · doi:10.13070/mm.en.4.827 · Cited by 2
Novel p53-Based Therapies: Strategies and Future Prospects
Laı́n, S., & Lane, D. P. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_16 · Cited by 2
Self-citationMDM2 and MDMX Regulators of p53 Activity
Momand, J. A., Aspuria, P. J., & Furuta, S. (2007) · Springer eBooks · doi:10.1007/0-387-30127-5_7 · Cited by 1
The new function of p53 family and its pathway related pro-teins in female reproduction
Zhu, H., Li, A., Yu, J., Xiang, C.-J., Su, S.-D., Huang, L., Fang, Y., Luo, Y., & Tang, W. (2012) · Hereditas (Beijing) · doi:10.3724/sp.j.1005.2012.00943 · Cited by 1
Purification of His-ubiquitin Proteins from Mammalian Cells
Olivares‐Illana, V., & Farhaeus, R. (2012) · BIO-PROTOCOL · doi:10.21769/bioprotoc.258 · Cited by 1
Aberrant RNA methylation triggers recruitment of an alkylation repair complexPreprint
Brickner, J. R., Tsao, N., Rodell, R., Oyeniran, C., Lukinović, V., Bacolla, A., Zhang, L., Soll, J. M., Casanova, A. G., Ganguly, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.28.271874 · Cited by 1
Role of the Adenovirus Type 5 L4-100K Protein During Lytic Infection
Koyuncu, O. Ö. (2009)
Defining the Role of CtBP2 in p53-Independent Tumor Suppressor Function of ARF: A Dissertation
Kovi, R. C. (2009) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/86d1-1y04
Regulation of the p53 Tumor‐Suppressor Protein by Ubiquitin and Ubiquitin‐Like Molecules
Xirodimas, D. P. (2007) · Wiley eBooks · doi:10.1002/9783527619320.ch2c
Self-citationFUNCTION OF ZNF668 IN CANCER DEVELOPMENT
Hu, R. (2011) · Digital Commons-TMC (Texas Medical Center)
Xenopus laevis as a model system for evaluating the function of fanconi anemia proteins
Stone, S. (2008) · Pure Amsterdam UMC
Post-translational Modifications of the p53 Transcription Factor
Brooks, C. L., & Gu, W. J. (2007) · Springer eBooks · doi:10.1007/978-0-387-40049-5_15
Quality assurance in interstitial iridium-192 implants for breast cancer
Petriz, L., Julve, J. V., Cinos, C., Monne, J. M. S., & Sala, F. (2002) · Revista de Oncología · doi:10.1007/bf02832108
Small molecules that affect the p53 pathway and their potential use in the treatment of cancer
Sachweh, M. C. C. (2014) · Figshare
Mathematical Models of Some Signaling Pathways Regulating Cell Survival and Death
Zhang, T., Tyson, J. J., Brazhnik, P., Li, L., Mendes, P., Finkielstein, C. V., & Burns, J. A. (2008) · VTechWorks (Virginia Tech)
Re-thinking the role of ribosomal proteins in the Mdm2-p53 axis
Daftuar, L. (2013) · doi:10.7916/d8cn739x
Estudio sobre funciones específicas de proteínas MAGE-I y su relevancia en oncología
de Toledo, M. F. P. (2015) · Repositorio Digital Institucional de la Universidad de Buenos Aires (Universidad de Buenos Aires)
Bailly, A., Perrin, A., Serrano‐Maciá, M., Maghames, C. M., Leidecker, O., Trauchessec, H., Martinez-Chantar, M., Gartner, A., & Xirodimas, D. P. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/583864
Self-citationRegulation of the p53 Tumor‐Suppressor Protein by Ubiquitin and Ubiquitin‐Like Molecules
Xirodimas, D. P. (2007) · Wiley eBooks · doi:10.1002/9783527620234.ch2
Self-citationHu, R., Peng, G., Dai, H., Breuer, E.-K. Y., Stemke‐Hale, K., Li, K., Gonzalez-Angulo, A. M., Mills, G. B., & Lin, S. (2023) · doi:10.1158/0008-5472.c.6502727.v1
Malhab, L. J. B. (2016) · theses.fr (ABES) · doi:10.70675/a9a79207z0857z4ed5zb207z749cdceb9430
The nuclear protein quality control system for the elimination of stress-induced aggregates
Brunello, L. (2021) · theses.fr (ABES) · doi:10.70675/ce9204b1z17c7z476bz9bd5z4e801e0613ef
Metadata
- Authors
- Xirodimas, D., Saville, M. K., Edling, C., Lane, D. P., & Laín, S.
- Affiliations
- University of Dundee (GB)
- Venue
- Oncogene
- Published
- 2001-08-16
- Volume
- 20
- Issue
- 36
- Pages
- 4972-4983
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2050259175
- Cited by
- 169
- References
- 37
- Citations by year
- 2024: 2 · 2023: 1 · 2021: 4 · 2020: 2 · 2019: 6 · 2018: 6 · 2017: 5 · 2016: 3 · 2015: 5 · 2014: 6 · 2013: 6 · 2012: 9
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- p14ARF, p53, MDM2, ubiquitination, polyubiquitination, monoubiquitination, proteasomal degradation, E3 ubiquitin ligase, protein stability, nucleolar localization signal, MG132, tumor suppressor regulation
- MeSH terms
- Animals, Cell Line, Cell Nucleolus, Cysteine Endopeptidases, Leupeptins, Multienzyme Complexes, Nuclear Proteins, Proteins, Proto-Oncogene Proteins, Transfection, Ubiquitins, Cysteine Proteinase Inhibitors, Tumor Suppressor Protein p53, Tumor Suppressor Protein p14ARF, Proteasome Endopeptidase Complex, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
